Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Harbin Pharmaceutical Group Co., Ltd. Warned by Harbin Bureau of Environment Protection
Harbin Pharmaceutical Group Co., Ltd. announced that it was warned by Harbin Bureau of Environment Protection due to the Company's pharmaceutical plants' violation of environment protection law.
Latest Developments for Harbin Pharmaceutical Group Co Ltd
- Harbin Pharmaceutical Group Co Ltd Applies for RMB 23.7 Billion Comprehensive Credit Lines
- Harbin Pharm Group Sanjing Pharmaceutical Co Ltd Announces Capital Injection into Subsidiary of Harbin Pharmaceutical Group Co., Ltd.
- Harbin Pharmaceutical Group Co., Ltd. Announces No Dividend Payment for FY 2011
- Harbin Pharmaceutical Group Co., Ltd. Announces Corrective Actions; Expects Influence on FY 2012 Net Profit
Latest Key Developments in Pharmaceuticals
- Tonghua Golden-Horse Pharmaceutical Industry Co Ltd Announces Changes of General Manager
- Merck & Co Inc Announces $5 Billion Accelerated Share Repurchase
- Herbalife Ltd Engages PricewaterhouseCoopers LLP As Auditors
- Drug regulator to probe Ranbaxy Laboratories Ltd's records, approvals in India-Business Standard
- Share this
- Link this
- Digg this
Follow Reuters